Our recent findings have demonstrated that Enho mRNA and protein levels are downregulated in the ischemic mouse brain, and treatment with synthetic adropin peptide can significantly reduce stroke-induced infarct volume, which was associated, in part, with restoration of endogenous adropin levels and increase in eNOS phosphorylation in the brain [9]. This evidence concerns the gene ENHO and Stroke.